CliCr® and CliCr® derivatives are available via Iris Biotech GmbH

As per 25 Jan 2023, Iris Biotech sells CliCr® and CliCr® reagents for non-GXP research purposes. For GXP applications, parties are to connect with Cristal Therapeutics. Read more information on

Cristal Therapeutics to collaborate with Lonza on CliCr

20230117 Lonza collaborates with Cristal Therapeutics “CliCr® is a powerful metal-free click chemistry technology for the life science industry which offers shorter reaction times and greater yields and hence attractive CoG than comparative reagents on the market. Our collaboration with Lonza will help to extend the impact of this innovative technology for use in straightforward […]

Synaffix licenses CliCr chemistry from Cristal Therapeutics

Truly emboldened by the signed license agreement with Synaffix as it underscores the potential of our unique CliCr® technology! This represents an important milestone in the execution of our strategy to commercialize CliCr® in different fields of diagnostic and therapeutic bioconjugates. Please contact us in case of any interest! Synaffix license CliCr Cristal Therapeutics

New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging

Maastricht, The Netherlands, 4 May 2022 – Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the publication of the results of the clinical PICCOLO study in the peer-reviewed journal, Advanced Materials1. This first-of-its-kind study2, part funded by an EU Horizon […]

BIO Digital

June 14-17 2021 BIO Digital Digital

BIO Europe Spring

March 22-25 2021 BIO Europe Spring Digital

LSX World Congress

February 01-05 2021 LSX World Congress Digital

Biotech Showcase

January 11-13 2021 Biotech Showcase Digital

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a […]

BIO Europe

October 26-29 2020 BIO-Europe Digital